NCI Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?” March 20, 2026Vol.52 No.11By Claire Marie Porter
NCI A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants March 20, 2026Vol.52 No.11By Paul Goldberg
NCI Letai: “From this point forward, it really is much more like business as usual at the NCI.” March 20, 2026Vol.52 No.11By Jacquelyn Cobb
Sponsored Early-onset colorectal cancer demands a new research playbook March 20, 2026Vol.52 No.11By Marwan Fakih
Conversation with The Cancer Letter Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.” March 13, 2026Vol.52 No.10By Paul Goldberg
Regulatory News Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again) March 13, 2026Vol.52 No.10By Claire Marie Porter
Regulatory News Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncologyAtara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” March 13, 2026Vol.52 No.10By Jacquelyn Cobb
Guest Editorial As more people are surviving cancer, we must continue funding bold science March 13, 2026Vol.52 No.10By Karen E. Knudsen
Cancer History ProjectFree The murder of Alexei Navalny is part of Russia’s macabre fascination with poisonsA gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison March 13, 2026Vol.52 No.10By Robert Peter Gale
News Analysis GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
